Vorasidenib’s FDA approval as a first-in-class dual IDH1/2 inhibitor marks a significant advance in treating grade 2 IDH-mutant gliomas, underscored by the INDIGO trial’s substantial progression-free survival benefit. This evidence concerns the gene IDH2 and glioma.